Clinical Omics Datasets

Disease-Specific Datasets with Genomic and Phenotypic Data

Robust, disease-specific datasets powered for statistical significance with whole genome data and detailed longitudinal clinical data.

Clinical Omics Datasets

Accelerate your target identification

Select for therapeutic area, geographic location, or ethnic background. Datasets contain genotypic data enriched with deep phenotypic data, and are statistically powered to distinguish signal from noise.

Powered for statistical significance

Robust datasets with data from thousands of pseudonymized participants for many disease, subtypes, and clinical features. Population control dataset with data from 15,000 individuals.

Participant consent and re-contact

Ability to re-contact fully consented patients for follow-up phenotypes, outcomes, and further samples. We ensure patient consent, and compliance with data protection and privacy.

Digitize your samples

Whole Genome and Whole Exome Sequencing from FFPE samples, blood, saliva, tissue, cultured cells, or dried blood spots.

Scalable GORdb platform

Our proprietary platform provides a holistic view of your own private data with that from public genomic databanks.

Powerful analytics crafted for genomics

Analytics and AI trained on multi-omic and phenotypic data. Proven in target discovery, drug response signatures, and population genomics.

Retrospective and Prospective Trials

Can be used for both prospective and retrospective studies

Clinical Omics Datasets

Europe, Asia, N. America

Data connecting across the globe

Our differentiated approach

  • Partner with healthcare providers, biopharma, government, foundations, and patient groups
  • Focus on homogeneous populations for better signal to noise resolution
  • Use WGS to fully leverage the genome
  • Disease specialists curate and validate deep phenotypic data
  • Supported by our full catalog of products and team of experts

Related items

New Approaches to the Old Hunt for NASH Therapies

In this webinar experts from across the pharma field discuss potential new targets and approaches for NASH therapy, and where the field will go in the near future.

Read More

Using Powered Cohorts to Speed Drug Discovery and Development

With the recent acquisition of Genomics Medicine Ireland (GMI, in Dublin), WuXi NextCODE is realizing the vision of turning advancements in genomics into improvements in drug discovery and ultimately population health, providing benefit to patients around the world.

Read More

The Rise of Population-scale Genomic Projects for Pharma R&D Investments

With the announced $400 million investment from global investors including the Irish sovereign fund, WuXi NextCODE announced that GMI would whole genome sequence and collect detailed medical data on 400,000 Irish volunteers covering 60 major diseases, partnering with life sciences companies to analyse the data for insights.

Read More